Course outline
Module 1
Module 1: Introduction to Metformin and Longevity
Introduction to Metformin and Longevity
Knowledge check
Q1. What is the primary use of Metformin?
- A. To treat hypertension
- B. To treat type 2 diabetes ✓
- C. To treat hyperthyroidism
- D. To treat depression
Why: Metformin is primarily used to treat type 2 diabetes by helping to control blood sugar levels.
Q2. Which of the following is a known side effect of Metformin?
- A. Weight gain
- B. Diarrhea ✓
- C. High blood pressure
- D. Insomnia
Why: Diarrhea is a common side effect of Metformin, especially when starting the medication or increasing the dose.
Q3. What is the main mechanism of action of Metformin?
- A. It increases insulin production in the pancreas
- B. It decreases glucose production in the liver and improves insulin sensitivity ✓
- C. It stimulates the release of glucagon
- D. It increases appetite
Why: Metformin works by decreasing glucose production in the liver and improving insulin sensitivity in muscle and fat cells.
Q4. In the context of longevity, what is Metformin often studied for?
- A. Cancer treatment
- B. Anti-aging properties ✓
- C. Alzheimer's disease prevention
- D. Heart disease treatment
Why: Metformin is often studied for its potential anti-aging properties and its role in extending lifespan in various research models.
Q5. Which of the following is a benefit of Metformin in addition to managing diabetes?
- A. It causes weight loss ✓
- B. It increases cholesterol levels
- C. It promotes inflammation
- D. It reduces physical activity
Why: Metformin is associated with weight loss in some individuals, which is an additional benefit beyond its role in managing diabetes.
Module 2
Module 2: Mechanisms of Action in Aging
Mechanisms of Action in Aging
Knowledge check
Q1. What is one of the primary mechanisms by which metformin may contribute to longevity?
- A. Promoting insulin resistance
- B. Activating AMPK ✓
- C. Inhibiting mitochondrial function
- D. Increasing oxidative stress
Why: Metformin activates AMPK, which plays a key role in cellular energy homeostasis and has been linked to longevity.
Q2. Which of the following is a known effect of metformin on aging-related pathways?
- A. Inhibiting mTOR ✓
- B. Enhancing NF-κB activity
- C. Reducing sirtuin expression
- D. Increasing DNA damage
Why: Metformin may inhibit mTOR, a pathway associated with aging and cellular senescence.
Q3. How does metformin affect mitochondrial function?
- A. It decreases mitochondrial biogenesis
- B. It increases mitochondrial ROS production
- C. It improves mitochondrial efficiency ✓
- D. It has no effect on mitochondria
Why: Metformin has been shown to improve mitochondrial efficiency and reduce oxidative stress in some studies.
Q4. Which of the following is a potential anti-aging effect of metformin?
- A. Promoting telomere shortening
- B. Enhancing autophagy ✓
- C. Reducing NAD+ levels
- D. Inhibiting DNA repair
Why: Metformin may enhance autophagy, a process that helps remove damaged cellular components and is associated with longevity.
Q5. What is the role of AMPK in the context of metformin and aging?
- A. It decreases cellular energy use
- B. It promotes inflammation
- C. It enhances metabolic health and longevity ✓
- D. It inhibits DNA replication
Why: AMPK activation by metformin is linked to improved metabolic health and potential anti-aging effects.
Module 3
Module 3: Clinical Trials and Evidence
Clinical Trials and Evidence
Knowledge check
Q1. Which of the following is a primary outcome measured in clinical trials evaluating metformin's effect on aging?
- A. Weight loss
- B. Reduction in mortality rates ✓
- C. Improved sleep quality
- D. Increased muscle mass
Why: Mortality rates are a key indicator of longevity and are often used as a primary outcome in aging-related clinical trials.
Q2. What is the name of the large-scale clinical trial currently investigating metformin's potential to extend lifespan?
- A. TAME ✓
- B. META
- C. LIFE
- D. AGE
Why: TAME stands for Targeting Aging with Metformin, and it is a major trial exploring metformin's effects on aging and longevity.
Q3. Which of the following conditions is metformin primarily used to treat?
- A. Hypertension
- B. Type 2 diabetes ✓
- C. Hyperlipidemia
- D. Obesity
Why: Metformin is a first-line medication for the treatment of type 2 diabetes.
Q4. What is one of the proposed mechanisms by which metformin may contribute to longevity?
- A. Increased insulin resistance
- B. Activation of AMPK
- C. Inhibition of mTOR
- D. All of the above ✓
Why: Metformin is known to activate AMPK, inhibit mTOR, and may improve insulin sensitivity, all of which are linked to longevity.
Q5. In clinical trials, metformin has been associated with a reduction in which of the following biomarkers of aging?
- A. Telomere length
- B. Inflammatory markers ✓
- C. Blood pressure
- D. Cholesterol levels
Why: Metformin has been linked to reduced levels of inflammatory markers, which are associated with aging and age-related diseases.
Module 4
Module 4: Metformin and Cellular Senescence
Metformin and Cellular Senescence
Knowledge check
Q1. What is cellular senescence?
- A. A process where cells continue to divide indefinitely
- B. A state where cells stop dividing and enter a stable growth arrest ✓
- C. A process of cell death
- D. A process of cell differentiation
Why: Cellular senescence is defined as a state where cells stop dividing and enter a stable growth arrest, often in response to stress or damage.
Q2. Which of the following is a key characteristic of senescent cells?
- A. Increased mitochondrial function
- B. Secretion of pro-inflammatory factors ✓
- C. Enhanced DNA repair
- D. Increased autophagy
Why: Senescent cells are known for secreting pro-inflammatory factors, often referred to as the senescence-associated secretory phenotype (SASP).
Q3. How does metformin potentially influence cellular senescence?
- A. By promoting cell division
- B. By reducing the accumulation of senescent cells ✓
- C. By increasing oxidative stress
- D. By inhibiting autophagy
Why: Metformin may help reduce the accumulation of senescent cells, thereby potentially delaying aging and age-related diseases.
Q4. What is the role of AMPK in the context of metformin and cellular senescence?
- A. It decreases cellular energy levels
- B. It promotes senescence
- C. It activates pathways that may delay senescence ✓
- D. It has no role in senescence
Why: AMPK activation by metformin can trigger pathways that may delay cellular senescence and promote cellular health.
Q5. Which of the following is NOT a potential benefit of reducing senescent cells?
- A. Improved tissue function
- B. Reduced inflammation
- C. Increased cancer risk ✓
- D. Enhanced organ function
Why: Reducing senescent cells is generally associated with reduced inflammation, improved tissue and organ function, and is not linked to increased cancer risk.
Module 5
Module 5: Metformin in Cardiovascular Health
Metformin in Cardiovascular Health
Knowledge check
Q1. What is one of the primary benefits of metformin in cardiovascular health?
- A. Increases heart rate
- B. Improves endothelial function ✓
- C. Causes arrhythmias
- D. Reduces blood pressure significantly
Why: Metformin has been shown to improve endothelial function, which is crucial for maintaining healthy blood vessels and cardiovascular health.
Q2. Which of the following is a known mechanism by which metformin may protect the heart?
- A. Inhibiting AMPK activity
- B. Activating AMPK activity ✓
- C. Blocking insulin receptors
- D. Increasing cholesterol levels
Why: Metformin activates AMPK, which plays a key role in improving mitochondrial function and protecting the heart from ischemic injury.
Q3. What effect does metformin have on blood pressure in patients with type 2 diabetes?
- A. It significantly increases blood pressure
- B. It has no effect on blood pressure
- C. It slightly decreases blood pressure ✓
- D. It causes hypertension
Why: Metformin is associated with a slight reduction in blood pressure, which contributes to its cardiovascular benefits.
Q4. Which of the following conditions is metformin commonly used to treat?
- A. Hypertension
- B. Type 2 diabetes mellitus ✓
- C. Hyperthyroidism
- D. Atherosclerosis
Why: Metformin is the first-line medication for the treatment of type 2 diabetes mellitus.
Q5. What is a potential risk of metformin use in patients with kidney disease?
- A. It increases kidney function
- B. It causes lactic acidosis ✓
- C. It lowers cholesterol levels
- D. It improves glucose control
Why: Patients with kidney disease are at higher risk of lactic acidosis when taking metformin, which is why it is contraindicated in severe renal impairment.
Module 6
Module 6: Metformin and Cancer Prevention
Metformin and Cancer Prevention
Knowledge check
Q1. What is one of the primary mechanisms by which metformin may help in cancer prevention?
- A. By increasing insulin levels
- B. By activating AMPK ✓
- C. By promoting cell division
- D. By reducing oxygen intake
Why: Metformin activates AMPK, which can inhibit cancer cell growth and proliferation.
Q2. Which of the following cancers has been most strongly associated with metformin use in research studies?
- A. Lung cancer
- B. Breast cancer
- C. Colorectal cancer ✓
- D. Prostate cancer
Why: Research has shown a strong association between metformin use and reduced risk of colorectal cancer.
Q3. How does metformin potentially affect the mTOR pathway in cancer prevention?
- A. It activates mTOR
- B. It inhibits mTOR ✓
- C. It has no effect on mTOR
- D. It increases mTOR activity in all cells
Why: Metformin may inhibit the mTOR pathway, which is involved in cell growth and proliferation, thus helping to prevent cancer.
Q4. What is a possible benefit of metformin in cancer prevention related to its effect on insulin resistance?
- A. It increases insulin resistance
- B. It decreases insulin resistance ✓
- C. It has no effect on insulin resistance
- D. It causes diabetes
Why: Metformin improves insulin sensitivity, which can reduce the risk of cancer by lowering insulin and IGF-1 levels.
Q5. Which of the following is a known side effect of metformin that is not directly related to cancer prevention?
- A. Weight loss
- B. Gastrointestinal discomfort ✓
- C. Reduced cancer risk
- D. Lowered blood sugar
Why: Gastrointestinal discomfort is a common side effect of metformin, but it is not directly related to its cancer-preventive properties.
Module 7
Module 7: Future Directions and Research
Future Directions and Research
Knowledge check
Q1. What is one of the primary areas of future research regarding metformin as a longevity drug?
- A. Its effects on skin aging
- B. Its potential to extend lifespan in humans ✓
- C. Its impact on hair growth
- D. Its role in improving sleep quality
Why: Research is focused on understanding whether metformin can increase human lifespan, which is a key aspect of longevity studies.
Q2. Which of the following is a potential mechanism by which metformin may promote longevity?
- A. Increasing insulin resistance
- B. Activating AMPK pathways ✓
- C. Reducing mitochondrial function
- D. Inhibiting autophagy
Why: Metformin is known to activate AMPK, a key pathway involved in cellular energy regulation and longevity.
Q3. What is a common concern in the research on metformin as a longevity drug?
- A. It is too expensive to produce
- B. It may have harmful side effects at high doses ✓
- C. It only works on men
- D. It is not available in pill form
Why: High doses of metformin may lead to gastrointestinal issues and vitamin B12 deficiency, which are concerns in longevity research.
Q4. Which of the following studies has explored the use of metformin in extending lifespan?
- A. The Framingham Heart Study
- B. The TAME (Targeting Aging with Metformin) trial ✓
- C. The Nurses' Health Study
- D. The Framingham Offspring Study
Why: The TAME trial is specifically designed to investigate whether metformin can delay aging and extend lifespan in humans.
Q5. What is a major limitation in current research on metformin's effects on longevity?
- A. Lack of interest from pharmaceutical companies
- B. Most studies have been conducted on animals rather than humans ✓
- C. Metformin is not approved for use in humans
- D. There is no interest from the public
Why: While animal studies show promise, human trials are limited, making it difficult to draw definitive conclusions about metformin's longevity effects.